Priority Research Paper Volume 9, Issue 3 pp 615—626

Physiological frailty index (PFI): quantitative in-life estimate of individual biological age in mice

Figure 4. Chronic treatment with rapamycin ameliorates HFD-induced health decline in male mice. (A) Rapamycin prevents HFD-induced weight gain in female but not in male mice (p<0.01, Student’s t-test). Green – HFD given with normal water, orange – HFD given in combination with rapamycin. (B) Kaplan-Meier survival curves for mice fed HFD in combination with normal drinking water (green line) or rapamycin (orange line). Chronic administration of rapamycin has no effect on longevity of both male (mean survival is 91.5+5.9 and 100.5+6.26 weeks) and female mice (mean survival is 104.9+7.7 and 110.5+7.6 weeks for control and rapamycin-treated mice respectively). Red arrow indicates the period of time when mice received rapamycin. Black arrow indicates time when PFI was measured. (C) PFI created at 78 weeks of age using 16 or 18 parameters for male and female mice respectively. Chronic administration of rapamycin ameliorates detrimental effect of HFD and brings the PFI values down to the normal range characteristic for this age (p=0.014, Student’s t-test). HFDW – high-fat diet in combination with regular drinking water (group 3), HFDR – high-fat diet in combination with rapamycin (group 4).